Is it okay to take 50mg of ensidipine?

Enasidenib is an oral, targeted inhibitor used to treat a specific type of acute myeloid leukemia (AML), which is a type of acute myeloid leukemia that patients with Patients with newly diagnosed, refractory or relapsed AML with IDH2 (isocitrate dehydrogenase2) mutations. The dosage and usage of the drug are usually based on the patient's specific condition and the recommendations of the doctor.

In the treatment ofAML, the usual recommended dose of ensidipine is 100mg once daily , which is the current standard recommended dose. This dose is often effective in controlling the progression of AML and has demonstrated some efficacy in clinical trials.

However, specific drug dosages may vary based on individual differences, severity of condition, and other factors. Before initiating ensidipine, patients should receive a detailed clinical evaluation and the most appropriate dosage and usage determined by their physician's advice. In addition, dose adjustments may also be made during treatment based on patient response and tolerability.

For some patients, doctors may consider reducing the dose to 50mg daily, especially those with medical conditions or other drug interactions. This dose reduction may help mitigate adverse effects and improve patient tolerance of treatment.

In general, the dose of ensidipine should be determined by the physician based on the patient's specific situation and disease characteristics. Patients should strictly follow the doctor's advice while using the drug and receive regular monitoring to ensure the safety and effectiveness of the drug.